N/A
N=35
Vitreous Inflammation in Standard and Heavy Silicone Oil
Vitreous Inflammation
Bottom Line
View on ClinicalTrials.gov: NCT02675543 ↗Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcome: Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Vitreous Tamponade with Silicone Oil (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Università degli Studi di Brescia
- Primary completion
- Dec 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Vitreous Prostaglandin E2 Levels |
369.38; 869.16 | — |
Summary
The inflammatory response after prolonged retinal detachment and after vitreoretinal surgery has its apex in the development of PVR that occurs when retinal cells are exposed to the inflammatory milieu in the humor vitreous.
This situation is common in complicated retinal detachment, but is amplified after invasive surgery and by the use of intraocular tamponades that float over a subtle film of liquid where the inflammatory cytokines and growth factors reach the critical concentration over the inferior retina.
Many authors have noted that the heavy tamponade are more prone to cause intraocular inflammation compared to standard silicone oil, especially if they remain for several months in the eye.
The purpose of this study is to measure the vitreous concentration of some of the most important cytokines involved in the inflammatory vitreal response.
Eligibility Criteria
Inclusion Criteria
- patient scheduled for vitrectomy
Exclusion Criteria
- diabetic retinopathy
- uveitis
Data sourced from ClinicalTrials.gov (NCT02675543). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.